United States: Cannabis In Animal Supplements: A Hazy Proposition

Over at our Life Sciences Decoded blog, we have discussed the state of limbo in which animal dietary supplements exist from a regulatory perspective. In the case of human products, foods, dietary supplements and drugs occupy three different regulatory areas, each with its own requirements, manufacturing standards and premarket application needs. Each also has unique regulatory systems. Food has HARPC and FSMA, drugs have generic versions and extraordinarily complex and expensive premarket approval requirements, and dietary supplements have unique labeling requirements. This is largely because of the Dietary Supplement Health and Education Act of 1994 (DSHEA) which delineated supplements from regular food products and from drugs designed to cure diseases.

The same delineation does not apply to products made for animal consumption. In 1996, and echoed in 2002, the FDA stated that DSHEA does not apply to products for animals. As a result, the FDA treats all products for animals as one of three main products:

  • Animal feed is defined as an article for food or animal consumption.
  • A feed additive is typically any substance which is expected to become a component of animal food either as an ingredient or by top dressing a feed or placement in the animal's water.
  • A drug is defined as an article intended for use in the diagnosis, cure, mitigation, treatment or prevention of disease. This includes Medicated Type A articles and the products derived from them, called medicated feeds.

A look at the animal supplement market reveals products similar to those products found in the human dietary supplement markets – products intended to affect or support a structure or function of the body. These products do not meet the definitions of a feed, feed additive or drug. Without the application of DSHEA, the result has been, to date, a virtually unregulated market.

Cannabis and animal products

The question, therefore, is what should the cannabis industry do when considering the production of cannabis-based supplement products for animals? What FDA regulation should these industry members expect? Last year, Life Sciences Decoded predicted that the majority of these animal supplement products would likely be considered foods and fall under the control of the FDA's new rules under the Food Safety Modernization Act (FSMA). This means they will be subject to significant oversight and regulatory requirements. Life Sciences Decoded covered the basics of these regulatory regimes generally but more specifically as they apply to animal products and include:

  • Hazard Analysis and Risk-based Preventive Controls (HARPC) for animal foods
  • The Sanitary Transport of Human and Animal Food

The question then becomes, will cannabis products meant for animals be treated as a food or drug by the FDA? The first and foremost place to look is, of course, the FDA. However, despite cannabis' continued Schedule I classification in the case of human uses, the FDA has been relatively silent on the use of cannabis in animal products. The closest the FDA has come to addressing the issue is a series of 2015 warning letters to members of the cannabis industry. Of those letters, one was directed toward Canna-Pet, LLC for four of its products aimed at dogs and cats. In this letter, the FDA determined that Canna-Pet's products were drugs under 21 U.S.C. § 321 (g)(1)(B) which defines a drug as "articles intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals."

In finding that the products were drugs, the FDA looked to Canna-Pet's own marketing claims related to these products, which included:

  • Antitumor, Antiepileptic, Anticancer, Anti-inflammatory, Bone stimulant, Analgesic, Anti-depressant, Antibacterial, Antipsoriatic, Antidiabetic, . . . Anti-nausea, Anti-anxiety, . . . Antipsychotic, . . . Immunosuppressive.
  • We Recommend Canna-Pet" as a daily food additive for all pets, but especially for those with arthritis, allergies, anxiety or behavior issues, compromised immune systems, diabetes, digestive issues, nausea, chronic pain, cancer, seizures, and those receiving palliative care.

The important distinction for the cannabis industry is that the FDA labeled Canna-Pet products as drugs not because they contained cannabis or cannabis extracts, but because the Canna-Pet products were, "intended to mitigate, treat, or prevent disease in animals, it is a drug." Under 21 U.S.C. §§ 360b, 360ccc and 360ccc-1, new animal drug products must be approved pursuant to a new animal drug application, the subject of a conditionally approved new animal drug application, or an index listing, respectively. Without these approvals, the FDA will find products for animals meeting the definition of a drug to be unsafe and adulterated under the FDCA. This means the FDA has the ability to issue warning letters, obtain injunctions against the sale of the products, and seize the products.

Impact of the Cole Memorandum and the Rohrabacher-Farr medical marijuana amendment

Currently, there are limitations as to how the federal government can pursue enforcement actions against members of the cannabis industry. Two major federal government actions are responsible for these limitations. First, the document known as the "Cole Memorandum," previously discussed here on Tracking Cannabis, is a statement by the Department of Justice (DOJ) that it will not pursue charges against individuals involved in, or participating in, the cannabis industries in states where there are rigorous and enforced regulatory systems to control cannabis products. In 2014, Congress passed the Rohrabacher-Farr medical marijuana amendment that stated:

None of the funds made available in this Act to the Department of Justice may be used, with respect to [states with cannabis legalization statutes] to prevent such States from implementing their own State laws that authorize the use, distribution, possession, or cultivation of medical marijuana.

Many in the industry see this as a free pass for cannabis businesses to operate without federal interference. Nothing could be further from the truth. First, the Rohrabacher-Farr amendment and Cole Memorandum apply only to medical cannabis programs, and do not apply to recreational cannabis use. Second, they only apply to the Department of Justice, and therefore its enforcement actions involving cannabis activities. This is a narrow set of activities the federal government cannot partake in, and generally does not apply to the FDA and its administrative or civil activities. In addition, to the foregoing, there is great concern over how the new administration will continue to view cannabis, particularly in light of the nomination of Jeff Sessions for U.S. Attorney General.

The prime example of this are the warning letters the FDA sent to members of the industry in 2015 and 2016. These letters represent meaningful enforcement actions against the cannabis industry, and these letters were spawned by a significant number of activities and situations. For example, one of the products that led to the Canna-Pets letters described above, despite advertising itself as CBD product, contained no cannabis or cannabis extracts at all. In addition, while no such actions have occurred yet, there is little reason why other federal agencies (such as the FTC regulating misleading advertising) could not regulate the cannabis industry.

Industry impact

What does this mean for members of the cannabis industry looking to produce products for animals? First, understanding that marketing terminology matters is key to positioning products not as drugs, but rather as foods or feeds not subject to the premarket approval process and clinical trial requirements for animal drugs.

Regulatory counsel can review your marketing and ensure that your products avoid making drug-like claims ("treats epilepsy" or "anti-tumor"). Second, avoiding classification as a drug is the first step to avoiding the FDA's enforcement activities. The second is ensuring that your internal processes meet all applicable regulatory requirements. This may include having a compliant food safety plan; an understanding of your suppliers not just of active ingredients but other ingredients and even packaging as well; and managing the safe and sanitary transportation of ingredients and finished products.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.